Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September

By Doug Macron

Spanish RNAi drug shop Sylentis expects to dose the first patient in a phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September, a company official confirmed to RNAi News this week.

The disclosure comes about a month after the company announced that it had received clearance from Spanish regulators to begin the trial, in line with its previously disclosed guidance (see RNAi News, 2/19/2009).